Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2].
Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft[2].
| Animal Model: | Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors[2] |
| Dosage: | 0, 0.1, 0.3, 1, 3, 10, 30, 100 μg |
| Administration: | Intraperitoneal injection (i.p.), twice weekly. |
| Result: | Dose-dependently inhibited tumor growth.
Induced caspase-3 activation in tumors (determined by IHC).
|
